Cargando…

(−)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes

Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) plays an important oncogenic role in the viral latent infection. Recently, increasing evidence indicates that the high expression of LMP1 during EBV lytic cycle is related to the viral lytic replication. However, the mechanism by whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hongde, Li, Yueshuo, Hu, Jianmin, Liu, Sufang, Luo, Xiangjian, Tang, Min, Bode, Ann M., Dong, Zigang, Liu, Xinqi, Liao, Weihua, Cao, Ya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420900/ https://www.ncbi.nlm.nih.gov/pubmed/33629943 http://dx.doi.org/10.3727/096504021X16135618512563

Ejemplares similares

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
por: Li, Hongde, et al.
Publicado: (2018)

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy
por: Hu, Jianmin, et al.
Publicado: (2020)

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum
por: Hu, Jianmin, et al.
Publicado: (2022)

Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance
por: Xie, Longlong, et al.
Publicado: (2020)

Conformational change of adenine nucleotide translocase‐1 mediates cisplatin resistance induced by EBV‐LMP1
por: Zhao, Lin, et al.
Publicado: (2021)

Correction: Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance
por: Xie, Longlong, et al.
Publicado: (2022)

Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis
por: Li, Hongde, et al.
Publicado: (2016)

EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter
por: Shi, Feng, et al.
Publicado: (2019)

EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs/HIF-1 pathway in nasopharyngeal carcinoma
por: Yang, Lifang, et al.
Publicado: (2015)

Computational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG)
por: Chen, Hanyong, et al.
Publicado: (2015)

The EBV-Encoded Oncoprotein, LMP1, Recruits and Transforms Fibroblasts via an ERK-MAPK-Dependent Mechanism
por: Davis, Alexandra M, et al.
Publicado: (2021)

Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs
por: Hong, Bangxing, et al.
Publicado: (2011)

The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells
por: Zeng, Mei, et al.
Publicado: (2020)

New Look of EBV LMP1 Signaling Landscape
por: Wang, Ling, et al.
Publicado: (2021)

Role of Epigallocatechin Gallate in Glucose, Lipid, and Protein Metabolism and L-Theanine in the Metabolism-Regulatory Effects of Epigallocatechin Gallate
por: Lin, Ling, et al.
Publicado: (2021)

EBV-Encoded LMP1 Upregulates Igκ 3′Enhancer Activity and Igκ Expression in Nasopharyngeal Cancer Cells by Activating the Ets-1 through ERKs Signaling
por: Liu, Haidan, et al.
Publicado: (2012)

Effects of epigallocatechin-3-gallate on bovine oocytes matured in vitro
por: Huang, Ziqiang, et al.
Publicado: (2018)

Conquering the Nuclear Envelope Barriers by EBV Lytic Replication
por: Lee, Chung-Pei, et al.
Publicado: (2021)

Skin Protective Effect of Epigallocatechin Gallate
por: Kim, Eunji, et al.
Publicado: (2018)

HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer
por: Lifang, Yang, et al.
Publicado: (2008)

Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma
por: Kamara, Saidu, et al.
Publicado: (2023)

Epigallocatechin-3-gallate and Epigallocatechin-3-O-(3-O-methyl)-gallate Enhance the Bonding Stability of an Etch-and-Rinse Adhesive to Dentin
por: Yu, Hao-Han, et al.
Publicado: (2017)

The protective role of (−)-epigallocatechin-3-gallate in thrombin-induced neuronal cell apoptosis and JNK-MAPK activation
por: He, Qianqian, et al.
Publicado: (2015)

In Vitro Evaluation of the Antiviral Activity of the Synthetic Epigallocatechin Gallate Analog-Epigallocatechin Gallate (EGCG) Palmitate against Porcine Reproductive and Respiratory Syndrome Virus
por: Zhao, Chunjian, et al.
Publicado: (2014)

The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate
por: Zeng, Jiajun, et al.
Publicado: (2018)

Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy
por: Granja, Andreia, et al.
Publicado: (2016)

Food-Grade Encapsulation Systems for (−)-Epigallocatechin Gallate
por: Shi, Meng, et al.
Publicado: (2018)

Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems
por: Granja, Andreia, et al.
Publicado: (2017)

Effect of Epigallocatechin Gallate on Viability of Kudoa septempunctata
por: Shin, Sang Phil, et al.
Publicado: (2020)

Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
por: Xie, Qianjin, et al.
Publicado: (2021)

Inhibition of autophagy in EBV-positive Burkitt's lymphoma cells enhances EBV lytic genes expression and replication
por: De Leo, A, et al.
Publicado: (2015)

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer
por: Wang, Liu-Xiang, et al.
Publicado: (2019)

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
por: Ramayanti, Octavia, et al.
Publicado: (2018)

Molecular Interactions between (−)-Epigallocatechin Gallate Analogs and Pancreatic Lipase
por: Wang, Shihui, et al.
Publicado: (2014)

Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues
por: WANG, AILIANG, et al.
Publicado: (2016)

Characterization of the Synergistic Antioxidant Activity of Epigallocatechin Gallate (EGCG) and Kaempferol
por: Zhang, Qiang, et al.
Publicado: (2023)

Epigallocatechin-3-Gallate Reduces Fat Accumulation in Caenorhabditis elegans
por: Liu, Jinning, et al.
Publicado: (2018)

The cytotoxic mechanism of epigallocatechin gallate on proliferative HaCaT keratinocytes
por: Chu, Yu-Wen, et al.
Publicado: (2017)

Neuroprotective Activity of (−)-Epigallocatechin Gallate against Lipopolysaccharide-Mediated Cytotoxicity
por: Liu, Jin-Biao, et al.
Publicado: (2016)

Contribution of the KSHV and EBV lytic cycles to tumourigenesis
por: Manners, Oliver, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dath8j4ppnlrl9r8sao594t856